Compass Therapeutics, Inc. SEC filings CMPX

Compass Therapeutics, Inc. has 359 filings in SEC EDGAR's recent list, going back to May 30, 2018. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 22, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 29, 2026 Dec 31, 2025
10-K Annual report Mar 5, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 29, 2025 Dec 31, 2024
10-K Annual report Feb 27, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 29, 2024 Dec 31, 2023
10-K Annual report Mar 21, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 27, 2023 Dec 31, 2022
10-K Annual report Mar 15, 2023 Dec 31, 2022
10-K Annual report Mar 18, 2022 Dec 31, 2021
10-K Annual report Mar 5, 2021 Dec 31, 2020
10-K Annual report Jun 8, 2020 Mar 31, 2020
10-K Annual report Jul 1, 2019 Mar 31, 2019

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CMPX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1738021
Former names
Olivia Ventures, Inc. (until Jun 8, 2020)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.